Press Releases Johnson & Johnson

Equities

JNJ

US4781601046

Pharmaceuticals

Market Closed - Nyse Other stock markets 23:00:02 14/05/2026 +03			Pre-market 02:08:08
230.80 ^USD	+0.16%		229.93	-0.38%

05-13	Leerink Partners Upgrades Johnson & Johnson to Outperform From Market Perform, Adjusts PT to $265 From $252	MT
05-12	Johnson & Johnson Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 11:20 AM

Press Releases

05-14	Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation	PR
05-14	Rising Scrutiny Of Employer Health Plan Administration: ERISA Fiduciary Litigation, Federal Transparency Initiatives, State Enforcement, And Compliance Considerations	AQ
05-13	Johnson & Johnson : showcases hematology leadership with 30+ presentations at the 2026 European Hematology Association (EHA) Congress	PU
05-12	Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter	BU
05-11	Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference	BU
05-11	Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP	PR
05-07	Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission	PR
05-07	Breach Of Contract, IP Rights, And Irreparable Harm: Lessons From The Third Circuit’s Stelara Decision	AQ
05-05	Johnson & Johnson : study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn’s disease	PU
05-05	Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease	PR
05-05	Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease	PR
05-05	Johnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic System	BU
05-05	Johnson & Johnson : Promising Data from US Pilot Study Shows Planned Impella 5.5 Use is Safe and Feasible in Non-Shock, High-Risk Cardiac Surgery Patients	PU
05-04	CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis	PR
05-04	Johnson & Johnson : to Present New Data Spanning Vision Portfolio at ARVO 2026	PU
05-01	Johnson & Johnson : STELARA® Pediatric Crohn’s Disease FDA Approval J&J Statement	PU
04-30	Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations	BU
04-29	Johnson & Johnson : ushers in the next wave of innovation in cancer care with more than 20 clinical and real-world studies at ASCO 2026	PU
04-28	Johnson & Johnson to Participate in the Bernstein's 42nd Annual Strategic Decisions Conference	AQ
04-27	Johnson & Johnson to Participate in the Bernstein’s 42nd Annual Strategic Decisions Conference	BU
04-27	FDA grants Priority Review for IMAAVY® (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA)	PR
04-24	Johnson & Johnson : First Quarter 2026 Earnings Infographic	PU
04-24	Johnson & Johnson : Enters Agreement to Acquire Atraverse Medical	PU
04-24	Johnson & Johnson : Launches Landmark Head-to-Head Pulsed Field Ablation Trial in Persistent Atrial Fibrillation	PU
04-22	Johnson & Johnson : Quarterly Report for Quarter Ending March 29, 2026 (Form 10-Q)	PU